Benitec Biopharma (NASDAQ:BNTC) Price Target Raised to $35.00

Benitec Biopharma (NASDAQ:BNTC) had its price objective upped by HC Wainwright from $28.00 to $35.00 in a research report report published on Tuesday, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Benitec Biopharma’s FY2026 earnings at ($1.65) EPS.

A number of other analysts have also recently issued reports on BNTC. Citizens Jmp raised their price objective on Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a research report on Tuesday. Wall Street Zen upgraded Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. Zacks Research cut shares of Benitec Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. Finally, Oppenheimer reissued an “outperform” rating and issued a $29.00 price objective (down from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.83.

Benitec Biopharma Stock Performance

NASDAQ BNTC opened at $12.00 on Tuesday. The firm has a market capitalization of $315 million, a P/E ratio of -8.16 and a beta of 0.23. The company has a current ratio of 54.67, a quick ratio of 54.67 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $14.52 and its two-hundred day moving average price is $13.78. Benitec Biopharma has a 1 year low of $9.10 and a 1 year high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.18). As a group, research analysts anticipate that Benitec Biopharma will post -1.48 EPS for the current year.

Institutional Trading of Benitec Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey acquired a new position in Benitec Biopharma in the 2nd quarter valued at $38,000. JPMorgan Chase & Co. bought a new stake in shares of Benitec Biopharma in the second quarter valued at about $80,000. Bank of America Corp DE boosted its position in shares of Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,587 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Benitec Biopharma in the second quarter valued at about $93,000. Finally, New York State Common Retirement Fund bought a new position in Benitec Biopharma during the second quarter worth about $95,000. 52.19% of the stock is currently owned by institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.